Cloning and expression of human vascular endothelial growth factor gene and inhibition of its expression by antisense in prokaryotic system by Yazdanfar, M. et al.
281 Tavakoli et al / DARU 2010 18 (4) 276-280
Filler S G. Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother, 1998; 
42: 2645-2649.
14.  Guinea J, Sanchez-Somolinos M, Cuevas O, Pelaez T, Bouza E. Fluconazole resistance mechanisms in 
Candida krusei: The contribution of efflux-pumps. Med Mycol, 2006; 44: 575-578.
15.  Zaini F, Kordbacheh P, Khedmati E, Safara M, Gharaeian N. Performance of five phenotypical methods 
for identification of Candida isolates from clinical materials Iranian  J Pub Health, 2006; 35: 25-32.
16.  Najafzadeh MJ, Falahati M, Pooshanga Bagheri K, Fata A , Fateh R, Fateh R. Flow cytometry susceptibility 
testing for conventional antifungal drugs and Comparison with the NCCLS Broth Macrodilution Test, 
DARU, 2009; 17: 94-98.
17.  Saffari M, Dinehkabodi OS, Ghaffari SH, Modarressi MH, Mansouri F, Heidari M. Identification of novel 
p53 target genes by cDNA AFLP in glioblastoma cells. Cancer Lett, 2009; 273: 316-22
18.  Ousati Ashtiani Z, Ayati M, Modarresi MH, Raoofian R, Sabah Goulian B, Greene WK, Heidari M. 
Association of TGIFLX/Y mRNA expression with prostate cancer. Med Oncol, 2009; 26: 73-7
19.  Aarabi M, Ousati-Ashtiani Z, Nazarian A, Modarressi MH, Heidari M. Association of TGIFLX/Y mRNA 
expression with azoospermia in infertile men. Mol Reprod Dev, 2008; 75: 1761-6 
20.  Henry KW, Nickels J.T, Edlind T.D. Upregulation of erg genes in Candida species by azoles and other 
sterol biosynthesis inhibitors. Antimicrobial agents and chemotherapy, 2000; 44: 2693-2700.
21.  Kakeya H, Miyazaki T, Miyazaki Y, Kono S. Azole resistance in Candida spp. Japanese Journal of Medical 
Mycology, 2003; 44: 87-92.
22.  Pinjon E, Moran GP, Jackson CJ, Kelly SL, Sanglard D, Coleman D.C, Sullivan DJ. Molecular mechanisms 
of itraconazole resistance in Candida dubliniensis. Antimicrobial agents and chemotherapy, 2003; 47: 
2424-2437.
23.  Chau AS, Gurnani M, Hawkinson R, Laverdiere M, Cacciapuoti A, McNicholas PM. Inactivation of 
sterol 5, 6-desaturase attenuates virulence in Candida abicans. Antimicrobial agents and chemotherapy, 
2005; 49: 3646-3651.
24.  Yan L, Zhang J, Li M, Cao Y, Xu Z, Cao Y, Gao P, Wang Y, Jiang Y. DNA microarray analysis of fluconazole 
resistance in a laboratory Candida albicans strain. Acta Biochim Biophys Sin, 2008; 40: 1048-1060.
25.  Venkateswarlu K, Denning D.W, Manning NJ, Kelly S.L. Reduced accumulation of drug in Candida 
krusei accounts for itraconazole resistance. Antimicrob Agents Chemother, 1996; 40: 2443-2446.
26.  Katiyar SK, Edlind TD. Identification and expression of multidrug resistance related abc transporter genes 
in Candida krusei. Medical Mycology, 2001; 39: 109-116.
27.  Lamping E, Ranchod A, Nakamura K, Tyndall JDA, Niimi K, Holmes AR, Niimi M, Cannon RD. Abc1p 
is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei. 
Antimicrobial Agents and Chemotherapy, 2009; 53: 354-369.
28.  Clark FS, Parkinson T, Hitchcock CA, Gow NA. Correlation between rhodamine 123 accumulation and 
azole sensitivity in Candida species: Possible role for drug efflux in drug resistance. Antimicrobial Agents 
and Chemotherapy, 1996; 40: 419-425.
29.  Marichal P, Gorrens J, Coene MC, Le Jeune L, Bossche HV. Origin of differences in susceptibility of 
Candida krusei to azole antifungal agents. Mycoses, 1995; 38: 111-117.
30.  Dimster-Denk D, Rine J. Transcriptional regulation of a sterol-biosynthetic enzyme by sterol levels in 
Saccharomyces cerevisiae. Molecular and Cellular Biology, 1996; 16: 3981-3989.
31.  Asai K, Tsuchimori N, Okonogi K, Perfect JR, Gotoh O, Yoshida Y. Formation of azole-resistant Candida 
albicans by mutation of sterol 14-demethylase p450. Antimicrobial agents and chemotherapy, 1999; 43: 
1163-1169.
32.  Beyer A, Hollunder J, Nasheuer HP, Wilhelm T. Post-transcriptional expression regulation in the yeast 
Saccharomyces cerevisiae on a genomic scale. Molecular & Cellular Proteomics, 2004; 3: 1083-1092.
Cloning and expression of human vascular endothelial growth factor 
gene and inhibition of its expression by antisense in prokaryotic system
1Yazdanfar M., 2Bandehpour M., 2Yarian F., 2Koochaki A, 1Parivar K., *2Kazemi B
 
1Islamic Azad University, Research and Sciences Campus, 2Cellular and Molecular Biology 
Research Center, Shahid Beheshti University of Medical Sciences,Tehran. Iran.
Received 2 May 2010; Revised 5 Dec 2010; Accepted 7 Dec 2010
ABSTRACT
Background and the purpose of the study: Angiogenesis is an important process in physiology 
and disease pathogenesis and is controlled in a healthy body by a number of stimulatory and 
inhibitory factors. The aim of this study was to determine the effect of antisense transcript on the 
sense transcript of the endothelial growth factor (EGF) gene in bacterial system as an approach 
for the gene regulation in tumors. 
Methods: The hepatoma cell line (HepG2) was stimulated by PMA. VEGF mRNA was used for 
RT-PCR. VEGF cDNA was synthesised and cloned into T-vector pTZ57R, then sense fragment 
of VEGF subcloned into pACYC Duet-1 expression vector and antisense VEGF subcloned 
into pCDNA3 expression vector. Recombinant plasmids were transforemed into BL21 bacterial 
cells. Expression of recombinant plasmid was analysed by western blot technique. 
Results: The recombinant pCDNA3-VEGF (pYZantiVEGF) was successfully expressed in 
BL21 cells. Western blot analysis showed that the expression of VEGF decreased significantly 
in the cells transfected with VEGF antisense RNA compared with the pACYCDUET-1 - VEGF 
(pYZsenseVEGF) transfected and control.
Major conclusions: The expression of VEGF in BL21 cells was strong. In vitro, antisense of 
VEGF inhibited VEGF expression significantly in BL21 cells.
Keywords: Angiogenesis, Recombinant plasmid, Antisense transcript, Vascular Endothelial 
Growth Factor (VEGF) 
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INTRODUCTION
Angiogenesis is the process of primary vascular 
plexus formation, involving the differentiation of 
endothelial cells from in situ mesoderm-derived 
precursor cells via sprouting or non-sprouting 
process (1).
Angiogenesis occurs physiologically during 
embryogenesis and early post-natal development, 
and also during the process of wound healing and the 
reproductive cycle in adults (2). It is a complex process 
that is tightly regulated by stimulatory and inhibitory 
factors and initiated when there is a predominance 
of angiogenic factors that favour new vessel growth 
(e.g. Vascular Endothelial Growth Factor (VEGF), 
Fibroblast Growth Factor (FGF), and transforming 
growth factors alpha and beta), are commonly 
known as the ‘angiogenic switch’(2). VEGF is one 
of the most potent regulators of angiogenesis, both 
physiologically and pathophysiologically (2). It is a 
potent mitogen, a survival factor for endothelial cells, 
and also mediates vessel permeability and migration 
of endothelial progenitor cells from the bone marrow. 
As VEGF is secreted by tumors, it has limited role in 
adults, and is a rational therapeutic target (2). VEGF 
promotes the growth of tumour vasculature to allow 
oxygen and nutrients to reach the rapidly dividing 
cancer cells. However, this tumour vasculature is 
abnormal both in structure and function, with the 
vessels being immature, leaky and tortuous, with 
a reduced or absence of supporting cells (2, 3). The 
VEGF family consists of six different homologous 
factors, VEGF-A, placental growth factor (PlGF), 
VEGF-B, VEGF-C, VEGF-D, and VEGF-E. Although 
VEGF-A, PlGF, VEFG-B, VEGF-D and VEGF-E are 
important for the growth of blood vessels and VEGF-C 
mainly affects the development of lymphatic vessels. 
Recent evidences suggest that VEGF-A, VEGF-B 
and VEGF-C directly affect neural cells (4). The two 
main classes of receptors for the VEGF family are the 
tyrosine kinase and the non-tyrosine kinase receptors. 
The former contains three structurally related 
receptors: VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-
1), and VEGFR-3 (Flt-4). The non-tyrosine receptors 
consist of neuropilin-1 (NP-1) and neuropilin-2 (NP-
2). The members of the VEGF family display different 
binding patterns to these receptors (5).
During the 1970s, the development of anti-
angiogenic agents was proposed as an effective     282 Cloning and expression of human vascular endothelial growth factor gene
anticancer strategy (2). Evidence shows that 
anti-VEGF agents possess a variety of in vivo 
mechanisms of action comprising early effects of 
the regression of existing tumor microvasculature 
and normalization of remaining tumor vasculature, 
as well as continued effects such as inhibition of 
new tumor vasculature. The mechanism of action 
of the anti-VEGF agents with regards to direct 
antitumor effects has not been fully elucidated, and 
it is only suggested that inhibition of the effects of 
VEGF on dendritic cell maturation may improve 
the immune response to tumors (2). Gene therapy 
through gene transfer might be a promising way. 
Antisense gene technologies have proved to be 
powerful tools for selective regulation of gene 
expression in experimental settings and are under 
evaluation for their therapeutic potentials in clinic 
(6). Antisense agents downregulate the expression 
of specific target genes at mRNA level by pairing 
with their complementary RNA and preventing their 
translations into proteins Theoretically, antisense 
molecules could be used to cure a variety of diseases, 
especially some cancers (6, 7).
Increased expression of VEGF by tumor-associated 
vasculature is a feature of many human and 
rodent tumors and correlated with tumor growth 
rate, microvessel density, proliferation, tumor 
metastatic potential and poorer patient prognosis 
in many malignancies (8). Growth inhibition of 
human tumor cell lines (sarcomas, carcinomas 
and gliomas by anti-human VEGF monoclonal 
antibodies generated in mice correlates with the 
almost complete suppression of tumor-associated 
angiogenesis (8). Several angiogenesis inhibitors 
are presently very hot drugs in the clinical 
market place as anticancer agents. Antisense 
gene technologies have proved to be powerful 
tools for selective regulation of gene expression 
in experimental settings and are under evaluation 
for their therapeutic potentials in clinic (9). In this 
study effects of antisense transcription on the sense 
transcript of EGF gene of E.coli was investigated.
MATERIALS AND METHODS
Cells and plasmids 
The HepG2 cell line (hepatocellular carcinoma) 
and pCDNA3 plasmid were gift from Dr.Naderian 
(Kashan University of Medical Sciences, Iran). 
The pACYCDuet-1 was purchased from Novagen 
(Germany).
Cell culture 
The HepG2 cell line was maintained in RPMI 
(Roswell Park Memorial Institute, Sigma, Germany) 
containing 2 mM L-glutamine (Sigma, Germany), 
100 U/ml penicillin (Sigma, Germany), and 100 μg/ml 
streptomycin (Sigma, Germany) supplemented with 
10% fetal bovine serum (Gibco, UK). The plateau 
level for these cultures was about 106 viable cells/ml. 
The sufficient flasks were induced by 50 ng of phorbol 
myristate acetate (PMA) (Sigma, Germany)
RNA extraction and PCR amplification
VEGF RNA was extracted from HepG2 cell line. 
This gene was amplified via RT-PCR reaction. PCR 
product (1000 bp) was visualized in 1.5 % agarose 
stained by syber green under ultraviolet light.
Gene cloning 
Amplified fragment was cloned in pTZ57R plasmid 
by T/A cloning. The recombinant plasmid (pTZ57R/ 
VEGF) was transformed into E. coli, XL1 blue 
strain competent cell. The recombinant plasmid 
was extracted and digested by BamHІ and HindIII 
restriction enzymes. 
The  purified  PCR  product  was  cloned  into 
BamHІ  and  HindIII digested pACYC DUET-
1 and pCDNA3 expression vectors as sense and 
antisense plasmids respectively (pYZsensVEGF 
pYZantiVEGF). These vectors were transformed in 
E. coli, BL21. Recombinant plasmid was confirmed 
by both colony PCR and enzyme digestion methods. 
PCR reaction was carried out by specific primers for 
VEGF gene.
Expression of recombinant protein
The  E. coli strain BL21 was transformed with 
the pACYC DUET-1/VEGF (pYZsensVEGF) 
and spread on Luria Bertani agar containing 50 
μg/ml  chloramphenicol.  The  transformant  strain 
was inoculated into 3 ml culture tube containing 
modified  YT  medium  (10)  and  allowed  to  grow 
at 37°C in a shaker at 160 rpm, overnight. The 
day after, it was sub-cultured into a 50 ml flasks 
containing YT medium and incubated at 37°C in a 
shaker, at 200 rpm. The culture in the logarithmic 
phase (at OD 600 = 0.6) was induced for 5 hrs and 
overnight  with 1 mM IPTG as inducer. Samples 
were withdrawn and analyzed on 10% (v/v) SDS-
PAGE, parallel with uninduced bacterial culture. 
The gel was stained with Coomassie brilliant blue 
R-250.
Transfer of sense and antisense plasmid in one 
bacterial host  
Because two plasmids (pYZsensVEGF and 
pYZantiVEGF) contained two different origins of 
replication and two different antibiotic resistance 
genes, after pYZsensVEGF was transformed into 
BL21 bacterial cell, and used as host for antisense 
plasmid (pYZantiVEGF). Bacteria were resistant to 
two antibiotics which were used for screening. Gene 
expression was analyzed by 10% SDS- PAGE and 
western blotting.
Western blot analysis 
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Western blot analysis 
Proteins resolved by SDS-PAGE were electro-
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phoretically transferred to a nitrocellulose 
membrane. The membranes was incubated in TBS 
(Tris-Buffered Saline containing 3% BSA (Bovine 
Serum Albumin) and then washed several times. 
The strips reacted with 1:200 dilution of anti VEGF 
monoclonal Ab (Anaspec.Cat.No.94555) and human 
serum respectively for one hour at 37°C.
The membrane was washed several times with TBS 
and TBS-T (TBS-Tween 20) and subsequently treated 
with horseradish peroxidase (HRP) conjugated 
sheep anti mouse Ig and rabbit anti human Ig at a 1: 
100 dilution for one hour at 37°C. The strips were 
visualized for color after development in Di Amino 
Benzidine/H2O2 substrate solution for 15 min at 
room temperature. The reaction was stopped by 
washing four times with distilled H2O.
RESULTS
VEGF RNA was extracted and subjected to PCR 
amplification and PCR product was electrophoresed 
on 1.5% agarose gel (Fig 1).
PCR product was ligated to pTZ57R/T vector and 
transformed into E.coli TOP10. White colonies 
containing recombinant plasmids were selected, 
extracted and electrophoresed on 0.8% agarose gel. 
For  confirmation,  the  recombinant  plasmid  was 
digested (VEGF/ pTZ57R) by BamHІ and HindIII 
restriction enzymes, and released 1000 bp (VEGF 
gene). The digested recombinant plasmid is shown 
in figure 2.
Digestion reaction was electrophoresed on LMP 
agarose gel and released DNA band was sliced and 
purified by DNA extraction kit (Fermentas cat NO. 
k0513) and sub-cloned into BamHІ  and HindIII 
digested pACYCDUET-1 expression vector and   
named pYZsensVEGF. 
For construction of VEGF antisense, HindIII  and 
BamHІ digested fragment were ligated into pcDNA3 
expression vector and named pYZantiVEGF. 
Subcloned  gene  in  these  vectors  were  confirmed 
using colony PCR, which was carried out by specific 
primers for VEGF gene (Fig 3).
SDS-PAGE
PYZsensVEGF was transformed into BL21 (DE3) 
E. coli and induced using 1 mM IPTG. Samples were 
taken before and at 3 hrs intervals after induction. 
The identity of the induced protein was confirmed 
by SDS-PAGE (Fig 4).
Western blotting  
The pYZsensVEGF was expressed and confirmed 
by western blot analysis, and no protein could be 
detected in the BL21 bacterial cells transformed by 
pYZsensVEGF and pYZantiVEGF (Fig 5).  
DISCUSSION
Angiogenesis is an important process in physiology 
and disease pathogenesis. Angiogenesis is controlled 
in a healthy body by a system of angiogenic 
growth factors and angiogenesis inhibitors. When 
angiogenic growth factors are predominantly 
expressed, blood vessel growth occurs and disease 
may result. Successful therapies that target growth 
factors, their receptors, or the cascade pathways that 
are activated by growth factor/receptor interactions 
have been developed. There is good evidence that 
angiogenesis plays an important role in a wide 
range of cutaneous maladies, and angiogenesis-
targeting therapies are playing an increasing role 
in the management of dermatological diseases. 
Cutaneous angiogenesis offers unexciting new 
arena for targeted dermatological therapeutics 
(11). Therapeutic approaches based on tumor 
angiogenesis have been divided into two 
major classes; (i) vasculostatic agents and (ii) 
vasculotoxins (11).
Tumor blood vessels are distinct from normal 
resting blood vessels, and this feature makes them 
good targets for cancer therapy. In order to block 
tumor growth and metastasis formation, a number of 
inhibitors targeting the tumor vasculature have been 
identified by in vitro and in vivo anti-angiogenesis 
studies (31, 32).
Antiangiogenic therapy targeting VEGF has been 
proposed as a means of inhibiting VEGF-dependent 
tumor growth and metastasis (9). 
There are three types of anti-mRNA strategies: 
1) Antisense oligonucleotide 2) Ribozyme/DNA 
Enzyme 3) Small interfering RNA. 
Antisense agents act at the mRNA level, 
preventing its translation into protein. Antisense-
oligonucleotides (AS-ONs) pair with their 
complementary mRNA, whereas ribozymes and 
DNA enzymes are catalytically active on ONs by 
binding and cleaving their target RNA. In addition, 
RNA interference has been established as a third 
highly  efficient  method  for  suppression  of  gene 
expression in mammalian cells by the use of 21-
23-mer small interfering RNA (siRNA) molecules 
(12). 
Rosen  et al have shown that SU668 has a wide 
spectrum of activity and inhibits the tyrosine kinase 
activity of PDGFR, FGFR1 and VEGFR2 (13). 
Schueneman and his collaborators have shown 
that SU011248 inhibits VEGFR1 and PDGFR 
equally (14). Hurwitz et al showed the efficiently 
of Bevacizumab, a humanized antibody designed 
to target VEGF (15). Posey et al. showed that IMC-
1C11, a chimerical IgG1 antibody against VEGFR2, 
is able to block ligand-receptor binding and inhibit 
phosphorylation (16). Niederman suggested that 
using VEGFR-specific CD8
+ cytotoxic lymphocytes 
as opposed to antibodies could well be an original 
approach (17).
In this study, it was aimed to suppress VEGF gene 
with the help of its antisense. The available drugs 
for angiogenesis suppression will apparently have 284 Cloning and expression of human vascular endothelial growth factor gene
effects on the produced protein while in this study 
the proposed method was to suppress protein 
expression at a transcriptional level. Compared to 
other available techniques for suppression of protein 
expression, the antisense technique is simpler and 
cheaper.
Antisense agents down-regulate the expression 
of specific target genes at mRNA level by pairing 
with their complementary RNA and preventing their 
translation into proteins. Theoretically, antisense 
molecules could be used to cure a variety of diseases, 
especially some cancers (9, 18, 19). VEGF plays 
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VEGF RNA was extracted and subjected to PCR 
amplification and PCR product was 
electrophoresed on 1.5% agarose gel (Figure1). 
 
Fig.1: Electrophoresis of PCR on 1.5% agarose gels. 
Line 1: The 1000 bp as PCR product of VEGF gene. 
Line 2: GeneRuller 100-3000bp DNA ladder marker 
 
PCR product was ligated to pTZ57R/ T vector and 
transformed into E.coli TOP10. White colonies 
containing recombinant plasmids were selected. 
Recombinant plasmid was extracted and 
electrophoresed on 0.8% agarose gel. For 
confirmation, the recombinant plasmid was 
digested (VEGF/ pTZ57R) by BamHІ and HindІІІ 
restriction enzymes, and released 1000bp (VEGF 
gene). The digested recombinant plasmid is shown 
in Fig 2. 
 
Fig.2: Electrophoresis on 1% LMP agarose gel  
 
Lane 1: Digested pTZ57R/VEGF by BamHІ & HindІІІ 
Lane 2: Digested pTZ57R/VEGF by BamHІ & HindІІІ 
Lane 3: GeneRuller 100-3000bp DNA ladder marker 
Lane 4: not digested pTZ57R/VEGF 
 
Digestion reaction was electrophoresed on LMP 
agarose gel and released DNA band was sliced 
and purified by DNA extraction kit (Fermentas cat 
NO. k0513) and sub-cloned into BamHІ  and 
HindІІІ digested pACYCDUET-1 expression 
vector and  named pYZsensVEGF.  
For construction of VEGF antisense, HindІІІ and 
BamHІ digested fragment were ligated into 
pcDNA3 expression vector and named 
pYZantiVEGF.  
Sub cloned gene in this vectors were confirmed 
using colony PCR, which was carried out by 
specific primers for VEGF gene (Figure 3). 
 
Fig 3: Orientation detection of cloned gene in 
expression Vector: 1.5% agarose gel electrophoresis of 
PCR product. 
 
 
6 
 
VEGF RNA was extracted and subjected to PCR 
amplification and PCR product was 
electrophoresed on 1.5% agarose gel (Figure1). 
 
Fig.1: Electrophoresis of PCR on 1.5% agarose gels. 
Line 1: The 1000 bp as PCR product of VEGF gene. 
Line 2: GeneRuller 100-3000bp DNA ladder marker 
 
PCR product was ligated to pTZ57R/ T vector and 
transformed into E.coli TOP10. White colonies 
containing recombinant plasmids were selected. 
Recombinant plasmid was extracted and 
electrophoresed on 0.8% agarose gel. For 
confirmation, the recombinant plasmid was 
digested (VEGF/ pTZ57R) by BamHІ and HindІІІ 
restriction enzymes, and released 1000bp (VEGF 
gene). The digested recombinant plasmid is shown 
in Fig 2. 
 
Fig.2: Electrophoresis on 1% LMP agarose gel  
 
Lane 1: Digested pTZ57R/VEGF by BamHІ & HindІІІ 
Lane 2: Digested pTZ57R/VEGF by BamHІ & HindІІІ 
Lane 3: GeneRuller 100-3000bp DNA ladder marker 
Lane 4: not digested pTZ57R/VEGF 
 
Digestion reaction was electrophoresed on LMP 
agarose gel and released DNA band was sliced 
and purified by DNA extraction kit (Fermentas cat 
NO. k0513) and sub-cloned into BamHІ  and 
HindІІІ digested pACYCDUET-1 expression 
vector and  named pYZsensVEGF.  
For construction of VEGF antisense, HindІІІ and 
BamHІ digested fragment were ligated into 
pcDNA3 expression vector and named 
pYZantiVEGF.  
Sub cloned gene in this vectors were confirmed 
using colony PCR, which was carried out by 
specific primers for VEGF gene (Figure 3). 
 
Fig 3: Orientation detection of cloned gene in 
expression Vector: 1.5% agarose gel electrophoresis of 
PCR product. 
Figure 1. Electrophoresis of PCR on 1.5% agarose gels.
Lane 1: The 1000 bp as PCR product of VEGF gene.
Lane 2: GeneRuller 100-3000 bp DNA ladder marker
Figure 2. Electrophoresis on 1% LMP agarose gel 
Lane 1: Digested pTZ57R/VEGF by BamHІ & HindІІІ
Lane 2: Digested pTZ57R/VEGF by BamHІ & HindІІІ
Lane 3: GeneRuller 100-3000 bp DNA ladder marker
Lane 4: not digested pTZ57R/VEGF
 
 
7 
 
 
Lane 1: 1000bp PCR product as VEGF gene for 
confirmed sub cloned gene in pACYCDUET-1 vector. 
(Using specific primer for VEGF)  
Lane 2: 1000bp PCR product as VEGF gene for 
confirmed sub cloned gene in pCDNA3 vector. (Using 
specific primer for VEGF)  
Lane 3: GeneRuller 100-3000bp DNA ladder marker 
 
SDS-PAGE 
PYZsensVEGF was transformed into BL21 (DE3) 
E. coli and induced using 1 mM IPTG. Samples 
were taken before and at 3 hrs intervals after 
induction. The identity of the induced protein was 
confirmed by SDS-PAGE (Figure 4). 
 
 
Fig 4: SDS-PAGE of bacterial lysate
 
Line 1: Lysate of BL21 cell 
Line 2: Lysate of BL21 cell containing intact 
pACYCDUET-1 
Line 3: Lysate of BL21 cell without induction 
containing pYZsensVEGF (0 h)  
Line 4: Lysate of BL21 containing pYZsensVEGF, 
collected 3h after induction  
Line 5: Lysate of BL21 containing pYZsensVEGF 
collected 5h after induction.  
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Line 1: Cell lysates containing pYZsensVEGF and 
pYZantiVEGF 3h after induction (expression 
suppression) 
Line 2: Cell lysates containing pYZsensVEGF 3h after 
induction (expression)  
 
DISCUSSION 
Angiogenesis is an important process in 
physiology and disease pathogenesis. 
Angiogenesis is controlled in a healthy body by a 
system of angiogenic growth factors and 
angiogenesis inhibitors. When angiogenic growth 
factors are predominantly expressed, blood vessel 
growth occurs and disease may result. Successful 
therapies that target growth factors, their 
receptors, or the cascade pathways that are 
activated by growth factor/receptor interactions 
have been developed. There is good evidence that 
angiogenesis plays an important role in a wide 
range of cutaneous maladies, and angiogenesis-
targeting therapies are playing an increasing role 
in the management of dermatological diseases. 
Cutaneous angiogenesis offers unexciting new 
arena for targeted dermatological therapeutics 
(11). Therapeutic approaches based on tumor 
angiogenesis have been divided into two major 
classes; (i) vasculostatic agents and (ii) 
vasculotoxins (11). 
Tumor blood vessels are distinct from normal 
resting blood vessels, and this feature makes them 
good targets for cancer therapies. In order to block 
tumor growth and metastasis formation, a number 
of inhibitors targeting the tumor vasculature have 
been identified in in vitro and in vivo anti-
angiogenesis studies (31, 32). 
Antiangiogenic therapy targeting VEGF has been 
proposed as a means of inhibiting VEGF-
dependent tumor growth and metastasis (9).  
There are three types of anti-mRNA strategies:  
1) Antisense oligonucleotide 
2) Ribozyme/DNA Enzyme 
3) Small interfering RNA  
Antisense agents act at the mRNA level, 
preventing its translation into protein. Antisense-
oligonucleotides (AS-ONs) pair with their 
complementary mRNA, whereas ribozymes and 
DNA enzymes are catalytically active on ONs by 
binding and cleaving their target RNA. In 
addition, RNA interference has been established 
as a third highly efficient method for suppression 
of gene expression in mammalian cells by the use 
of 21–23-mer small interfering RNA (siRNA) 
molecules (12).  
Rosen et al have shown  that SU668 has a wide 
spectrum of activity and inhibits the tyrosine 
kinase activity of PDGFR, FGFR1 and VEGFR2  
Figure 5. Immunoblotting.
Lane 1: Cell lysates containing pYZsensVEGF and pYZantiVEGF 
3hrs after induction (expression suppression)
Lane 2: Cell lysates containing pYZsensVEGF 3hr after induc-
tion (expression) 285 Cloning and expression of human vascular endothelial growth factor gene
effects on the produced protein while in this study 
the proposed method was to suppress protein 
expression at a transcriptional level. Compared to 
other available techniques for suppression of protein 
expression, the antisense technique is simpler and 
cheaper.
Antisense agents down-regulate the expression 
of specific target genes at mRNA level by pairing 
with their complementary RNA and preventing their 
translation into proteins. Theoretically, antisense 
molecules could be used to cure a variety of diseases, 
especially some cancers (9, 18, 19). VEGF plays 
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VEGF RNA was extracted and subjected to PCR 
amplification and PCR product was 
electrophoresed on 1.5% agarose gel (Figure1). 
 
Fig.1: Electrophoresis of PCR on 1.5% agarose gels. 
Line 1: The 1000 bp as PCR product of VEGF gene. 
Line 2: GeneRuller 100-3000bp DNA ladder marker 
 
PCR product was ligated to pTZ57R/ T vector and 
transformed into E.coli TOP10. White colonies 
containing recombinant plasmids were selected. 
Recombinant plasmid was extracted and 
electrophoresed on 0.8% agarose gel. For 
confirmation, the recombinant plasmid was 
digested (VEGF/ pTZ57R) by BamHІ and HindІІІ 
restriction enzymes, and released 1000bp (VEGF 
gene). The digested recombinant plasmid is shown 
in Fig 2. 
 
Fig.2: Electrophoresis on 1% LMP agarose gel  
 
Lane 1: Digested pTZ57R/VEGF by BamHІ & HindІІІ 
Lane 2: Digested pTZ57R/VEGF by BamHІ & HindІІІ 
Lane 3: GeneRuller 100-3000bp DNA ladder marker 
Lane 4: not digested pTZ57R/VEGF 
 
Digestion reaction was electrophoresed on LMP 
agarose gel and released DNA band was sliced 
and purified by DNA extraction kit (Fermentas cat 
NO. k0513) and sub-cloned into BamHІ  and 
HindІІІ digested pACYCDUET-1 expression 
vector and  named pYZsensVEGF.  
For construction of VEGF antisense, HindІІІ and 
BamHІ digested fragment were ligated into 
pcDNA3 expression vector and named 
pYZantiVEGF.  
Sub cloned gene in this vectors were confirmed 
using colony PCR, which was carried out by 
specific primers for VEGF gene (Figure 3). 
 
Fig 3: Orientation detection of cloned gene in 
expression Vector: 1.5% agarose gel electrophoresis of 
PCR product. 
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Lane 1: 1000bp PCR product as VEGF gene for 
confirmed sub cloned gene in pACYCDUET-1 vector. 
(Using specific primer for VEGF)  
Lane 2: 1000bp PCR product as VEGF gene for 
confirmed sub cloned gene in pCDNA3 vector. (Using 
specific primer for VEGF)  
Lane 3: GeneRuller 100-3000bp DNA ladder marker 
 
SDS-PAGE 
PYZsensVEGF was transformed into BL21 (DE3) 
E. coli and induced using 1 mM IPTG. Samples 
were taken before and at 3 hrs intervals after 
induction. The identity of the induced protein was 
confirmed by SDS-PAGE (Figure 4). 
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collected 5h after induction.  
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Yazdanfar et al / DARU 2010 18 (4) 281-285
an important role in the angiogenesis. The use of 
antisense VEGF RNA for inhibiting vessel formation 
might be a rational approach. 
CONCLUSION 
It was shown that VEGF expression was inhibited 
by antisense molecule in mRNA transcription level 
in prokaryotic system.  
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